Dr. John Wallenburg joined Cystic Fibrosis Canada as Chief Scientific Officer in March 2015. Dr. Wallenburg spent much of the last 25 years at the interface of technology creation and development. At the Ontario Institute for Cancer Research (OICR) he established the Commercialization infrastructure (now FACIT) and launched its first investment program. He served as President and Chair of TORCell Therapeutics, Inc, and sat on the Board of DLVR Therapeutics, Inc, both UHN-OICR startups. Prior to the OICR, John managed the Life Sciences group of the Office of Technology Transfer at McGill University. He served as a member of the CIHR’s Proof of Principle program review committee and from 2003–2006, he was a member of the Intellectual Property and Data Release Group of the International Hap Map Project. He’s been a product manager and a research scientist and in 1996 co-founded Morphogenesis, Inc., a biotechnology company in Florida. John is also a CF parent.
Join Team CFCanada for the Scotiabank Toronto Waterfront Marathon (STWM) with both in-person and virtual race options!
*See event listing for more information*Read More